[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614232":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":53,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":18,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":81,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tamsulosin Group","EXPERIMENTAL","The experimental group will receive Tamsulosin Hydrochloride Sustained-Release Capsules (0.2 mg, once daily at night) starting 3 days before the biopsy and continuing until the 6th day after the procedure (10 doses total).",[13],"Drug: Tamsulosin 0.2mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants will not receive Tamsulosin during the perioperative period but will undergo the standard prostate biopsy procedure.",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Tamsulosin 0.2mg",[9],[25],"Tamsulosin Hydrochloride Sustained-Release Capsules",[27],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},"Kai Zhang, Doctor Degree","CONTACT","+8618909870823","yaokaifeng@pku.edu.cn",[33],{"facility":34,"status":18,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Peking University First Hospital, Urology Department","Beijing","Outside U.S.\u002FCanada","100034","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":49,"phoneExt":18,"email":50},"Kai Dr. Zhang, Doctor degree","0086-10-83575602","kaizhangpku@163.com",{"type":52,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[54],{"name":55,"class":6},"Taiyuan Central Hospital of Shanxi Medical University","100614232","phase-4-perioperative-tamsulosin-for-treating-voiding-dysfunction-following-prostate-biopsy-100614232",false,"NCT07276919","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy: A Multicenter, Randomized, Controlled, Open-Label Study","Inclusion Criteria:\n\n* Male, aged 40 to 85 years (inclusive).\n* Meets indications for prostate biopsy per clinical guidelines (e.g., suspicious nodule on digital rectal exam, suspicious lesion on imaging, tPSA \\>10 ng\u002FmL, or tPSA 4-10 ng\u002FmL with f\u002Ft \\\u003C0.16 or PSAD \\>0.15).\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Previous prostate surgery, urinary diversion, or intermittent catheterization.\n* Use of alpha-adrenergic blockers (e.g., Tamsulosin, Doxazosin) within one week prior to screening.\n* Known or suspected allergy\u002Fintolerance to Tamsulosin, or history of orthostatic hypotension.\n* Indwelling urinary catheter or suprapubic cystostomy tube at the time of biopsy.\n* History of severe bleeding disorders.\n* Poorly controlled or unstable comorbidities such as hypertension or diabetes.\n* Severe immunosuppression.\n* Severe psychological disorders or uncooperative for the biopsy procedure.\n* Active urinary tract infection or neurogenic bladder.\n* Any other condition deemed by the investigator as unsuitable for participation.","MALE","40 Years","85 Years",{"count":67,"type":68},1844,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","The goal of this clinical trial is to learn if the drug Tamsulosin Hydrochloride works to treat urination difficulties after a prostate biopsy in men.The main questions it aims to answer are:\n\n* Does Tamsulosin Hydrochloride lower the rate of Acute Urinary Retention (inability to urinate) after a prostate biopsy?\n* Does Tamsulosin Hydrochloride improve participants' urination symptoms, quality of life, urine flow rate, and post-void residual urine volume?\n\nResearchers will compare the drug group to a control group (receiving no preventive medication) to see if Tamsulosin Hydrochloride works to prevent urination problems.\n\nParticipants will:\n\n* Be randomly assigned to either take Tamsulosin Hydrochloride or receive no preventive medication.\n* If in the drug group, take one capsule of Tamsulosin Hydrochloride every night, starting 3 days before the biopsy and continuing until 6 days after the biopsy (10 doses total).\n* Undergo a standard prostate biopsy procedure (either through the rectum or perineum).\n* Return to the clinic 7 days after the biopsy for a follow-up checkup, which will include questions about their symptoms (IPSS and QoL scores) and tests to measure urine flow and bladder emptying.",[74,75],"Acute Urinary Retention","LUTS(Lower Urinary Tract Symptoms)",[77,78,79,80],"acute urinary retention","LUTS(Lower urinary tract symptoms)","tamsulosin","prostate biopsy","NOT_YET_RECRUITING","2025-12-20",{"date":84,"type":85},"2025-12-23","ACTUAL",{"date":87,"type":68},"2026-02-01",{"date":89,"type":68},"2028-01-01",{"name":5,"class":6},1]